Zavesca (Miglustat) - Summary

ZAVESCA SUMMARY

ZAVESCA® (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first step in the synthesis of most glycosphingolipids. ZAVESCA® is an N-alkylated imino sugar, a synthetic analogue of D-glucose.

ZAVESCA® is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous access).

See all Zavesca indications & dosage >>

ZAVESCA NEWS HIGHLIGHTS

Published Studies Related to Zavesca (Miglustat)

Motion analysis of a child with Niemann-Pick disease type C treated with miglustat. [2008.01]

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. [2007.10.01]

Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. [2007.10]

Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. [2007.10]

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. [2007.09]

more >>

Clinical Trials Related to Zavesca (Miglustat)

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis [Active, not recruiting]

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses [Completed]

Miglustat in Niemann-Pick Type C Disease [Active, not recruiting]

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease [Completed]

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis [Recruiting]

more >>